Preventing and treating hepatitis B infection

被引：39

作者：

Aggarwal, R ^{[1
]}

Ranjan, P ^{[1
]}

机构：

[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Gastroenterol, Lucknow 226014, Uttar Pradesh, India

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2004年 / 329卷 / 7474期

关键词：

D O I：

10.1136/bmj.329.7474.1080

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hepatitis B virus infection is a global public health problem. Hepatitis B vaccines are highly effective, long acting, and safe, making prevention and even eventual eradication possible. However, treatment options for patients who are already infected are limited. The currently available drugs are effective only in selected subsets of patients and have low efficacy rates, and their long term impact on occurrence of complications remains unknown.

引用

页码：1080 / 1086

页数：7

共 34 条

[21]

3.0.CO

[22]

2-I

[23] Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B [J].

Manesis, EK ;

Hadziyannis, SJ .

GASTROENTEROLOGY, 2001, 121 (01) :101-109

[24] Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B [J].

Marcellin, P ;

Chang, T ;

Lim, SG ;

Tong, MJ ;

Sievert, W ;

Shiffman, ML ;

Jeffers, L ;

Goodman, Z ;

Wulfsohn, MS ;

Xiong, S ;

Fry, J ;

Brosgart, CL ;

Afdhal, N ;

O'Conner, C ;

Andreone, P ;

Cursaro, C ;

Angus, P ;

Vaughan, R ;

Bain, V ;

Gutfreund, K ;

Barange, K ;

Duffant, M ;

Barnes, E ;

Bennett, M ;

Pressman, J ;

Bernstein, D ;

Bonino, F ;

Coco, B ;

Borum, M ;

Schuck, S ;

Bourliere, M ;

Benali, S ;

Boyer, N ;

Castelnau, C ;

Brown, R ;

Scales, S ;

Buggisch, P ;

Peterson, J ;

Cooksley, G ;

MacDonald, G ;

Couzigou, P ;

Foucner, D ;

Crawford, D ;

Der, A ;

Desmond, P ;

Boussioutas, A ;

DiBisceglie, A ;

Bacon, B ;

Dieterich, D ;

Goldman, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (09) :808-816

[25] ACUTE HEPATITIS-B VIRUS-INFECTION - RELATION OF AGE TO THE CLINICAL EXPRESSION OF DISEASE AND SUBSEQUENT DEVELOPMENT OF THE CARRIER STATE [J].

MCMAHON, BJ ;

ALWARD, WLM ;

HALL, DB ;

HEYWARD, WL ;

BENDER, TR ;

FRANCIS, DP ;

MAYNARD, JE .

JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (04) :599-603

[26] Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B [J].

Niederau, C ;

Heintges, T ;

Lange, S ;

Goldmann, G ;

Niederau, CM ;

Mohr, L ;

Haussinger, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (22) :1422-1427

[27] Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B [J].

Perrillo, RP ;

Lai, CL ;

Liaw, YF ;

Dienstag, JL ;

Schiff, ER ;

Schalm, SW ;

Heathcote, EJ ;

Brown, NA ;

Atkins, M ;

Woessner, M ;

Gardner, SD .

HEPATOLOGY, 2002, 36 (01) :186-194

[28] A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis [J].

Perrillo, RP ;

Wright, T ;

Rakela, J ;

Levy, G ;

Schiff, E ;

Gish, R ;

Martin, P ;

Dienstag, J ;

Adams, P ;

Dickson, R ;

Anschuetz, G ;

Bell, S ;

Condreay, L ;

Brown, N .

HEPATOLOGY, 2001, 33 (02) :424-432

[29] Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B [J].

Peters, MG ;

Hann, HW ;

Martin, P ;

Heathcote, EJ ;

Buggisch, P ;

Rubin, R ;

Bourliere, M ;

Kowdley, K ;

Trepo, C ;

Gray, DF ;

Sullivan, M ;

Kleber, K ;

Ebrahimi, R ;

Xiong, S ;

Brosgart, CL .

GASTROENTEROLOGY, 2004, 126 (01) :91-101

[30] HEPATITIS-B VACCINE - DEMONSTRATION OF EFFICACY IN A CONTROLLED CLINICAL-TRIAL IN A HIGH-RISK POPULATION IN THE UNITED-STATES [J].

SZMUNESS, W ;

STEVENS, CE ;

HARLEY, EJ ;

ZANG, EA ;

OLESZKO, WR ;

WILLIAM, DC ;

SADOVSKY, R ;

MORRISON, JM ;

KELLNER, A .

NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (15) :833-841

← 1 2 3 4 →